ESC 365 - Doxapram is a promising new antiarrhythmic drug for an atrial-specific therapy of atrial fibrillation

ESC Premium Access

Doxapram is a promising new antiarrhythmic drug for an atrial-specific therapy of atrial fibrillation

Session: Novelties in atrial fibrillation and flutter management

Topic: Cellular Electrophysiology

Speaker: Professor C. Schmidt (Heidelberg, DE)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Constanze Schmidt

University Hospital Heidelberg, Heidelberg (Germany)

5 presentations

0 follower

5 more presentations in this session

The incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit

Speaker: Mrs M. Jacobs (Groningen, NL)

Typical atrial flutter is a manifestation of previously silent coronary artery disease

Speaker: Mr L. Iden (Bad Segeberg, DE)

Pericardial fat volume outperforms classic risk markers in the prediction of relapse after pulmonary vein isolation

Speaker: Doctor J. Carmo (Carnaxide, PT)

Zero-fluoroscopy catheter ablation of right- and left-sided supraventricular tachycardias

Speaker: Doctor M. Jan (Ljubljana, SI)

Pulsed Field Ablation: Acute and Chronic Safety and Lesion Efficacy

Speaker: Doctor A. Verma (Montreal, CA)

Access the full session

Novelties in atrial fibrillation and flutter management

Speakers: Professor C. Schmidt, Mrs M. Jacobs, Mr L. Iden, Doctor J. Carmo, Doctor M. Jan...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources